Kornimate/medical-research-clean huggingface dataset:
nmp22 provides improved sensitivity in detecting bladder cancers.

Conditions: Bladder Cancer

Summary: it is hypothesized that the nmp22(nuclear matrix protein) bladder check ® test will demonstrate improved sensitivity over that of standard urine cytology for patients with superficial transitional cell carcinoma at high risk of recurrence.

patients who have been previously treated for bladder cancer and are at a high risk for recurrence are being monitored for recurrence every 3 months with urine cytology and cystoscopy as part of standard care.the nmp22 bladder cancer ® test kit has been designed to provide an alternative to regular urine cytology. a urine sample will be provided and divided with a portion being used to assess the nmp22 test kit and the remaining sample to be sent to the lab for regular urine cytology. patient charts will be reviewed by a medical student to record age, clinical stage, pathologic stage, time to disease progression/recurrence, site of recurrence and survival data.

Eligibility criteria:
inclusion criteria: * · history of ptis, pt1, large (\>2cm) pta or multiple pta bladder cancer tumours. written informed consent prior to any study-related procedures. exclusion criteria: * history of bladder cancer tumours other than those listed in inclusion

Keywords: detection of bladder cancer using nmp22 urine test kit
observational study on efficacy and safety of liraglutide in subjects with type 2 diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: this observational study is conducted in europe. the aim of this non-interventional (observational) study is to evaluate the efficacy of liraglutide (victoza®) and to assess the conditions of use of victoza® in daily medical practice in france.


Eligibility criteria:
inclusion criteria: * patients diagnosed with type 2 diabetes * patients having recently started (for less than one week) or starting liraglutide (victoza®) treatment exclusion criteria: * hypersensitivity (allergy) to liraglutide or to any of the excipients * patient is participating in a clinical trial at the inclusion * type 1 diabetes
the effect of different treatment modalities of tubal ectopic pregnancy on ovarian reserve: a prospective cohort study

Conditions: Ectopic Pregnancy

Summary: detect the effect of different treatment modalities of tubal ectopic pregnancy on ovarian reserve


Eligibility criteria:
inclusion criteria: * the study will include patients aged 18-44 years with known diagnosis or suspicion of diagnosis of tubal ectopic pregnancy (abnormal doubling rates of their b-hcg levels as well as ultrasonographically identified or unidentified gestational sacs outside the uterus) * included patients must have capacity to provide informed consent. given the potential emergent nature of presentation, women will not be recruited if fully informed consent could be compromised due to a highly distressed emotional state or significant hemorrhage necessitating the need for urgent surgery exclusion criteria: 1. the use of hormonal contraceptives within two months of enrolment 2. if other surgery was conducted at the time of salpingectomy. 3. if a woman was pregnant at follow up visit for amh measurement 4. history of previous surgeries of fallopian tubes and/or ovaries
evaluation of ecg transmission and ai models using apple watch ecgs and symptoms data collected using a mayo iphone app

Conditions: Heart Failure; Arrhythmias, Cardiac; Health Care Utilization

Summary: the purpose of the study is to determine if the electrocardiograms (ecgs) and symptoms data obtained from an apple watch and transmitted to mayo clinic are of sufficient quality to guide a person's care.

1. patients who have the mayo clinic patient app and ios 14 or higher who are 18 years of age or older will be invited to enroll. 2. patient will undergo email survey to assess ownership of apple watch v4 or later, and subsequent willingness to participate in the study. those who agree will undergo digital consent and enrollment. 3. a customized mayo clinic study app will be available to download to their ios device and will be used to test whether it is feasible to access ecgs and symptoms data patients have collected using their personal apple watch that are saved on the patient's phone. the study app will facilitate transmission of past and future patient-recorded watch ecgs. 4. the patient ecgs and self-reported symptoms data will be uploaded to the ai dashboard in the patient's medical record (ecg rhythm classification facilitated by apple ecg program). 5. we will perform a retrospective review of electronic medical record data from enrolled subjects to assess the quality of the apple watch obtained ecgs, assess the results from the ai-ecg dashboard using obtained watch ecgs, and compare these results to prior or subsequently obtained 12 lead ecgs. 6. data analysis will be performed with steps to ensure patient confidentiality. data will be transmitted using similar protocols as with current app data, and all data will be saved in the secure mayo clinic electronic environment (called the udp). 7. all patients' watch data will be compared to ai dashboard data. additionally, clinical data in the emr (such as blood tests, echocardiograms, and other data recorded for routine medical care) will be used to assess the utility of the watch ecg quality for ai algorithms (such as determining whether a weak heart pump is present, for example).

Eligibility criteria:
inclusion criteria: - using the mayo patient iphone app. (determined automatically via mayo software). exclusion criteria: - inability to provide informed consent.

Keywords: digital health artificial intellegence neural network electrocardiogram wearable device
effectiveness of the single implant-retained mandibular overdenture treatment

Conditions: Mouth, Edentulous

Summary: this study aims to evaluate the treatment with single implant overdenture for the edentulous mandible. the investigators hypothesize that treatment with lower overdenture retained by a single implant appears to have satisfactory effectiveness as a treatment for patients with specific conditions (such as maladaptive patients), with the advantages of simplicity and greater immediate benefits when compared to the conventional full denture, improving the retention and stability of the denture and better oral-related quality of life.

this study is a longitudinal evaluation of clinical and patient-reported outcomes related to the single-implant mandibular overdenture treatment. sixty completely edentulous individuals will be included. first, new complete dentures will be fabricated for all of them. panoramic radiographs and conventional tomograms of the mandibular midline region will be obtained in order to plan the implant placement surgery. after the adaptation period related to the use of the new dentures, a single implant (titamax it cortical, neodent, curitiba, brazil) will be installed in the mandibular midline of all participants. according to the primary stability obtained in the implant placement patients will be treated with an immediate loading protocol when achieving torque of at least 30 ncm and implant stability quotient (isq) of at least 60. in cases of values below cited, conventional loading protocol will be adopted. ball o-ring will be used as the attachment system for the mandibular overdenture. clinical and patient-reported outcomes will be collected after 1, 3, 6 and 12 months after the installation of the overdentures.

Eligibility criteria:
inclusion criteria: * fully edentulous patients * need of replacement of the mandibular denture or patient without mandibular denture * patients with poor adaptation to the mandibular denture * patients with good general health exclusion criteria: * patients who refuse to receive a conventional dentures opposed to a mandibular overdenture retained by a single implant * patients with local intraoral diseases that influence denture stability, retention and adaptation of the lower denture (such as changes or anatomical deformations of the jaws, mucosal changes caused by fungi and bacteria, tumor changes and absolute xerostomia) * patients with systemic, psychological or neurological diseases that preclude or hinder oral movements of the patient for clinical care and/or clinical follow-up in all stages of the research * patients who choose other treatment modalities not covered by the study * patients with alcoholism or other severe behavioral disorders that compromise their participation in the study

Keywords: mandibular prosthesis implantation prostheses and implants denture, complete, lower
safety and tolerability study of medi-551, a b-cell depleting agent, to treat relapsing forms of multiple sclerosis

Conditions: Multiple Sclerosis, Relapsing Forms

Summary: the purpose of this study is to evaluate the safety and tolerability of ascending intravenous (iv) and subcutaneous (sc) doses of medi-551 in adult subjects with relapsing forms of multiple sclerosis (ms).

this is a phase 1, multicenter, multinational, randomized, blinded, placebo-controlled, dose-escalation study to evaluate the safety and tolerability of iv and sc doses of medi-551 in adult subjects with relapsing forms of ms.

Eligibility criteria:
inclusion criteria: * confirmed relapsing form of ms (ie, rrms, spms, prms, or cis) according to revised 2010 mcdonald criteria and mri brain lesions consistent with ms on screening * at least 1 documented relapse within the past 3 years prior to screening * edss between 0.0 and 6.5 at screening * have no more than 20 gd-enhancing t1 brain lesions detected by cranial mri scan exclusion criteria: * subjects with impaired renal function * major surgery within 8 weeks of the screening visit * subjects who are unable to undergo cranial mri scan * a history of hypersensitivity to gd-containing mri contrast agents * has received within 1 year prior to screening: monoclonal antibodies, experimental b-cell depleting agents, or treatment with natalizumab (tysabri) for greater than 3 months * receiving monthly methylprednisone or equivalent glucocorticoid for disease modification of a relapsing form of ms * known sensitivity to acetaminophen/paracetamol, diphenhydramine or equivalent antihistamine, methylprednisolone or equivalent glucocorticoid, or to any component of the investigational drug * diagnosis of ppms, neuromyelitis optica, or other non-ms variant of neuro-inflammatory or demyelinating diseases * any history of opportunistic infection or the presence of active infection within two months prior to screening or any herpes zoster infection that has not resolved within 12 weeks prior to screening * any clinically significant findings during the screening phase, including physical, neurological, laboratory, or ecg examination as per protocol

Keywords: mab, b cell, depletion, rms
subcutaneous cardiac monitoring of patients with btk inhibitors

Conditions: Atrial Fibrillation

Summary: the goal of this clinical trial is to screen all types of electrocardiographic changes and rhythm disorders in adult patients with a hematologic malignancy requiring a treatment by bruton's tyrosine kinase (btk) inhibitor (ibrutinib, acalabrutinib, zanubrutinib) using an insertable subcutaneous cardiac monitor (iscm) and occurring from inclusion and within 12 months. this study consists of the implantation of an iscm at inclusion and before btk inhibitor initiation. then patients will have medical visits every 3 months (+/- 7 days) during 12 months and a continuous cardiac telemonitoring using the iscm.


Eligibility criteria:
inclusion criteria: * adult patients, * definite diagnosis of hematologic malignancy requiring a btk inhibition with ibrutinib, acalabrutinib or zanubrutinib, * expected btk inhibitor duration estimated to be at least 12 months, * sinus rhythm at enrolment, * willing to sign patient consent form and to comply with scheduled visits, as outlined in the protocol exclusion criteria: * age \< 18 years old, * adults with protective measures (curatorship or tutorship) and vulnerable patients, * pregnant or nursing women, * permanent atrial fibrillation or long-standing persistent atrial fibrillation as defined by the european society of cardiology guidelines, * atrial fibrillation on the electrocardiogram at the inclusion visit, * previous left atrial ablation or previous maze or maze-like surgery, * indication for or patients with a pacemaker or implantable cardioverter-defibrillator at baseline, * untreated hyperthyroidism, * uncorrected kaliaemia disorders at the inclusion visit, * hemoglobin \< 8 g/l at the inclusion visit, * thrombopenia \< 50,000/mm3 at the inclusion visit, * active bleeding, * myocardial infarction \< 1 month, * surgery \< 1 month, * mechanical heart valve, * valvular heart disease requiring surgery, * inability to follow the required procedures of the clinical investigation plan, * no signature of patient consent form.

Keywords: cardio-oncology cardiotoxicity hematologic malignancy atrial fibrillation rhythm disorders insertable subcutaneous cardiac monitor
assess efficacy in subjects with traumatic spinal cord injury

Conditions: Erectile Dysfunction; Spinal Cord Injury

Summary: assess efficacy of vardenafil in patients with traumatic spinal cord injury


Eligibility criteria:
inclusion criteria: * men between 18 and 64 years old with stable cord injury (more than 6 months) who had erectile dysfunction according to the national institutes if health (nih) after their traumatic spinal cord injury exclusion criteria: * primary hypoactive sexual desire * history of myocardial infarction, stroke or life-threatening arrhythmia within prior 6 month * nitrate therapy

Keywords: spinal cord injury urodynamic erectile dysfunction vardenafil
study of pregnancy pathologies associated with placental abnormalities

Conditions: Pre-eclampsia; Pre-Term; Fetal Growth Retardation

Summary: pregnancy pathologies can occur from implantation until childbirth. the investigators are interested in the development mechanisms of these pathologies and aim to develop therapies to treat them. the investigators need to collect samples, especially placental samples, following abortions and term and premature deliveries. abortions will allow investigators to have non-pathological placental material up to 13 weeks. this material will serve as a reference for the understanding of the histological changes that occur in normal placentas collected at term of pregnancy. the latter will, in turn, be compared with the placentas collected during premature deliveries. also, the abortion product will be cultivated in an environment mimicking the pathology of pre-eclampsia. this study will allow investigators to advance their understanding of the pathophysiological mechanisms of the placenta. the investigators are internationally recognized for their research on these pathologies.

pregnancy pathologies can occur from implantation until childbirth. clinical and scientific investigators are interested in the study of the mechanisms of development of these pathologies and aim to develop therapies to treat them. the investigators need to collect samples, especially placental samples, following abortions, term, and premature deliveries. abortions will allow investigators to have non-pathological placental material up to 13 weeks. this material will serve as a reference for understanding the histological changes that occur in normal placentas collected at term of pregnancy. the latter, will in turn, be compared with the placentas collected during premature deliveries. also, the abortion product will be cultivated in an environment mimicking the pathology of preeclampsia. this study will allow investigators to advance the understanding of the pathophysiological mechanisms of the placenta. the investigators are internationally recognized for its research on these thematic.

Eligibility criteria:
inclusion criteria: adult women * admitted to the chuga for a birth or an abortion. * pregnant women consenting to the collection of their fetal placenta membranes, during premature deliveries or at term of pregnancy or women performing an abortion consenting to the collection of their abortion products. * having signed a consent * affiliated with social security exclusion criteria: * placental sample or abortion product unavailable (not collected or necessary for treatment). * patient with known positive hiv or hepatitis b or hepatitis c serology or at risk according to the infectious safety criteria applied by the efs. * hemoglobin \<7d / dl or hemoglobin \<10g / dl if she suffers from a cardio-respiratory pathology). * patient protected by law (minor, hospitalized under duress, subject to a legal protection measure by guardianship or curatorship, deprived of liberty by judicial or administrative decision)

Keywords: pre-eclampsia fetal growth retardation placenta histology vascularization trophoblast proliferation
assessment of metabolic response in critically ill patients with acute renal failure

Conditions: Acute Renal Failure

Summary: we hypothesize that a nutritional supplementation with higher than standard protein content (2.0 gm/kg/day vs 1.4 gm/kg/day) will result in improved whole-body net protein balance when administered to critically ill patients with acute renal failure (arf).


Eligibility criteria:
inclusion criteria: * adults ≥ 18 years of age admitted to the intensive care unit * new onset acute renal failure (arf) or arf superimposed on chronic kidney disease * arf will be defined by a sustained (over 24 hours) increase in serum creatinine \> 0.5 mg/dl from baseline * patients will be recruited for the study within 3-5 days following establishment of arf exclusion criteria: * institutionalized patient * previous kidney transplant * pregnancy * unable to obtain consent from subject or legally recognized representative * arf from urinary tract obstruction or a volume responsive pre-renal state. * liver failure * recent cerebrovascular accident (cva) * coagulopathy defined as: platelets \ 20, inr \> 2.0 if the patient requires the placement of an arterial or venous catheter; if the patient does not require the placement of an arterial or venous catheter for the study, coagulopathy will not be a basis for exclusion. * life expectancy \< 48 hours
effects of animal-assisted therapy on brain-injured patients

Conditions: Impaired Social Functioning

Summary: the purpose is to investigate whether animal-assisted therapy has positive biopsychosocial effects on patients with brain injuries. this study investigates the short-term biopsychosocial effects that occur when animals are present during therapy sessions in comparison to therapy sessions without animals, observing a group of 25 patients over 24 therapy sessions. while half of the sessions are held in presence of an animal and half without, they are as comparable as possible with respect to content and setting. in this study, patients who are in a slightly advanced rehabilitation process, assessed via their function profile, are investigated.

this study is designed as a controlled cross-over, within-subject trial with repeated measurement. the experimental condition is the standardised therapy session using therapy animals (aat), while the control condition is the comparable "standard" therapy session without the presence of an animal. over a period of six weeks, patients have four standardised therapy sessions per week, that alternate in a way that two sessions in two consecutive weeks are similar except for one is with the presence of animals and one without. in this way, data is collected over 24 therapy sessions (12 experimental, 12 control) for each patient. each therapy session lasts 30 minutes with an additional 5 minutes before and 10 minutes after the session for filling in the questionnaires. the study takes place at rehab basel. animal-assisted therapies will be held at the "therapie-tiergarten" at rehab basel in the presence of one or more animals that will be selected by the therapist and the patient together and with which the patient has a relationship. patients who are willing to join the study will be selected and allocated randomly to start with either the experimental or the control condition. participation in the study will be cancelled if a patient wishes to do so or if they choose to withdraw from the animal-assisted therapy program. other criteria for withdrawal are if the patient is harmed by an animal or if the animals are abused by the patient.

Eligibility criteria:
inclusion criteria: * patient at rehab basel * brain-injury * willing to participate in animal-assisted therapies * physical and psychological resilience and ability to go/be transported outside to the "therapie-tiergarten" * ability to get in contact with the animal autonomously exclusion criteria: * medical contraindications:allergies, phobias, etc. * no willingness to participate in animal-assisted therapies * patient might present a danger to the animals (aggressive behaviour) * patient's medication changes radically during the time of data collection

Keywords: animal assisted intervention, brain injury, rehabilitation
natalizumab treatment of progressive multiple sclerosis

Conditions: Primary Progressive Multiple Sclerosis; Secondary Progressive Multiple Sclerosis

Summary: the purpose of this study is to study safety and efficacy of natalizumab treatment of primary and secondary progressive multiple sclerosis. this will be done by measuring the effect of treatment on inflammation in the cns by means of osteopontin levels in the cerebrospinal fluid (csf). safety measures further includes physical and neurological examination,blood samples and mri measures of disease activity.

the study will include 12 secondary progressive multiple sclerosis patients and 12 primary progressive multiple sclerosis patients to treatment with iv natalizumab for 60 weeks. at baseline and week 60 a lumbar puncture will be performed. mri scans will be performed at baseline week 12 and week 60.safety blood samples will be collected every 12 week.

Eligibility criteria:
inclusion criteria: * age between 19 and 55 years * progressive disease course of multiple sclerosis (primary or secondary) * duration of progressive phase of at least 1 year * progression of \> 1 edss point during the last 2 years (\>½ edss point if edss \> 5,5) * edss \</= 6.5 * written and informed consent exclusion criteria: * pregnancy, breast-feeding or lack of anti.conception for fertile women. * attack during the last month before inclusion. * treatment with methylprednisolone during 3 months before inclusion. * treatment with interferon-beta, glatirameracetate, immunoglobulin g or other immune-modulating treatment 3 months prior to inclusion. * treatment with mitoxantrone, cyclophosphamide, azathioprine or other strong immunosuppressive drug 6 months prior to inclusion. * prior experimental treatment with strong immunosuppressive drug which the treating physician means will influence the results of the trial. * diseases associated with immunodeficiency. * treatment with other anticoagulant than aspirin. * current malign disease. * diabetes mellitus or other autoimmune disease. * renal insufficiency or creatinine \> 150 μmol/l. * travel in tropical areas 3 months prior to inclusion. * acute or chronic infectious diseases, which the treating physician finds relevant (e.g.hepatitis b virus, hepatitis c virus, hiv). * psychiatric disease or other circumstances that may limit the patients participation in the trial. * contraindication for mri scan or gadolinium contrast . * known hypersensitivity to natalizumab.

Keywords: primary progressive multiple sclerosis secondary progressive multiple sclerosis natalizumab treatment safety efficacy cerebrospinal fluid osteopontin